Cantor Fitzgerald Believes Paratek Pharmaceuticals (NASDAQ: PRTK) Still Has Room to Grow

By Ryan Adsit

In a report released today, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Paratek Pharmaceuticals (NASDAQ: PRTK), with a price target of $50. The company’s shares opened today at $24.95, close to its 52-week high of $26.10.

Chen commented:

“OASIS-2 study met all of its primary and secondary endpoints required to support approval for this indication by the FDA and EMA. This represents the third positive Phase 3 registration study of omadacycline (the other two were skin and pneumonia).”

According to, Chen is ranked 0 out of 5 stars with an average return of -11.8% and a 38.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Sucampo Pharmaceuticals, and ANI Pharmaceuticals Inc.

Paratek Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $41.

Based on Paratek Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $18K and GAAP net loss of $27.67 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $30.28 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Its products include Omadacycline and Sarecycline. The company was founded in February 2001 and is headquartered in Boston, MA.